A coronavirus study published a couple of weeks ago in The Lancet said that out of 96,000 patients treated for COVID-19 in hundreds of hospitals around the world, some 15,000 were given hydroxychloroquine or chloroquine.

Given the broad scope of the study, the World Health Organization (WHO), as well as several countries, paused other hydroxychloroquine studies.

The co-authors of the study have now retracted it, announcing that an independent review of the data wasn’t possible.

A study that used data from the same company, and had some of the same co-authors, was published in the New England Journal of Medicine (NEJM) several weeks ago.

They were unable to complete an independent audit of the data underpinning their analysis.

As a result, they have concluded that they “can no longer vouch for the veracity of the primary data sources.” The Lancet takes issues of scientific integrity extremely seriously, and there are many outstanding questions about Surgisphere and the data that were allegedly included in this study.

Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article, “Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.”1 We therefore request that the article be retracted.

As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process,” three of the hydroxychloroquine study researchers wrote — Dr.